دورية أكاديمية
The effect of tocilizumab on severe COVID-19 infection: Review of current evidence.
| العنوان: | The effect of tocilizumab on severe COVID-19 infection: Review of current evidence. |
|---|---|
| عنوان ترانسليتريتد: | Ağır COVID-19 enfeksiyonunda tosilizumab'ın etkinliği: Güncel çalışmaların derlemes. |
| المؤلفون: | Yakar Hİ; Department of Chest Diseases, Gaziosmanpaşa University Research and Practice Hospital, Tokat, Turkey., Pazarlı AC; Department of Chest Diseases, Gaziosmanpaşa University Faculty of Medicine, Tokat, Turkey., İnönü Köseoğlu H; Department of Chest Diseases, Gaziosmanpaşa University Research and Practice Hospital, Tokat, Turkey., Kanbay A; Clinic of Chest Diseases, İstanbul Göztepe Training and Research Hospital, İstanbul, Turkey. |
| المصدر: | Tuberkuloz ve toraks [Tuberk Toraks] 2021 Mar; Vol. 69 (1), pp. 74-83. |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: İstiklâl Matbaacılık ve Gazetecilik Koll. Ort Country of Publication: Turkey NLM ID: 0417364 Publication Model: Print Cited Medium: Internet ISSN: 0494-1373 (Print) Linking ISSN: 04941373 NLM ISO Abbreviation: Tuberk Toraks Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Ankara : İstiklâl Matbaacılık ve Gazetecilik Koll. Ort., [1953]- |
| مواضيع طبية MeSH: | SARS-CoV-2* , COVID-19 Drug Treatment*, Antibodies, Monoclonal, Humanized/*therapeutic use, Biomarkers/blood ; COVID-19/blood ; COVID-19/epidemiology ; Cytokines/blood ; Humans ; Pandemics |
| مستخلص: | The COVID-19 outbreak that spread in December 2019 has caused the death of millions of people in a short time. Many studies published recently have shown that many cytokines (interleukin (IL) IL-1, IL-2, IL-6, TNF and IFN-) are significantly increased in COVID-19 patients with pneumonia, and especially IL-6 in combination with other cytokines has shown to be the main cause of the cytokine storm. Since IL-6 level is associated with clinical worsening in COVID-19 patients, anti-IL-6 therapy is seen as a promising treatment. Tocilizumab, a widely used IL-6 antagonist, was approved by the FDA in 2017 for Cytokine Storm Syndrome (CSS). Its addition to the treatment in COVID19 patients with increased blood IL-6 levels and oxygen saturation. |
| المشرفين على المادة: | 0 (Antibodies, Monoclonal, Humanized) 0 (Biomarkers) 0 (Cytokines) I031V2H011 (tocilizumab) |
| تواريخ الأحداث: | Date Created: 20210415 Date Completed: 20210517 Latest Revision: 20221207 |
| رمز التحديث: | 20221213 |
| DOI: | 10.5578/tt.20219909 |
| PMID: | 33853308 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 0494-1373 |
|---|---|
| DOI: | 10.5578/tt.20219909 |